Sign in
CompletedNo phase

Precision Assessment of Platelet Rich Plasma for Joint Preservation

Key facts

Who runs it
VA Office of Research and Development
Where
Palo Alto, United StatesSee the site
Trial code
Status
Completed
People taking part
90 people enrolled
Started
2 Apr 2018
Ended
31 Mar 2024
Type of study
Observational
Record updated
23 May 2025

Who can take part

Age
30 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • symptomatic early knee OA
  • full weight-bearing status
  • have elected to receive PRP treatment
  • Male veterans
  • Female veterans

Who cannot take part

  • severe systemic disease defined as American Society of Anesthesiologists (ASA) 3 or above56
  • predominantly patellofemoral disease
  • inflammatory arthritis, gout or recurrent pseudogout
  • symptomatic OA of other lower extremity joints
  • BMI >35 kg/m2
  • use of walking, orthopedic, or prosthetic assistive device
  • inability to have MRI
  • pregnant or intending to become pregnant during the study

Where in United States

  • VA Palo Alto Health Care System, Palo Alto, CAPalo Alto, United States

About the trial

What the trial wants to find out

Knee Osteoarthritis (OA) is a leading cause of premature disability in Veterans who develop knee OA at higher rates and younger ages than the population in general. For those with symptomatic early knee OA, who are years to decades away from meeting clinical indications for knee replacement surgery, knee injections have been a key treatment option. In recent years, platelet rich plasma (PRP) injections have gained increasing attention for improving pain and function in patients with knee OA. Basic science studies also suggest that PRP may also potentially stimulate repair responses to articular cartilage. However, the mechanisms of action of PRP in the treatment of knee OA are unknown. Because autologous blood is used, the PRP composition differs between patients. It is also unknown whether these differences in PRP composition affect clinical outcomes. This study will address these gaps and provide critical new and objective information on PRP treatment effects in Veterans and additional women with early knee OA important to improving clinical use of this new treatment.

The group in the trial

  • PRP

    Symptomatic early knee osteoarthritis subjects who have elected to receive PRP treatment.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 May 2025